Tim Harris, CEO of Structural GenomiX, Leads The Way from Structures to Drug Leads | GenomeWeb

Tim Harris is bulldog-aggressive about making deals with pharma, but he’s no bull in a china shop.

The Structural GenomiX CEO, who has 25 years of experience in the field, at both big pharma and small biotech, plans to strategically maneuver his company into the trenches of pharmaceutical research, through a mixture of outside collaborations using protein structure-based drug discovery with its beamline X-ray crystallography technology, and internal discovery work.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.